# Clinical Trial: Cannabis Abstinence and Neurocognitive Assessment in Adolescence

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/ced-botanical-chemistry-mobile-cud-interventions-2026-11-02/
> **Published:** 2026-11-02T21:24:55-04:00 | **Last Modified / Clinically Audited:** 2026-11-02T21:24:55-04:00
> **Clinical Summary:** cannabis news digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan.

---

CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments.

Clinical Insight | CED Clinic
Plant anatomy dictates chemical delivery. Capitate-stalked trichomes on female floral bracts contain high densities of THC and terpenes, while vegetative leaves hold lower cannabinoid concentrations dominated by sessile structures. When patients consume whole-flower formulations, their exposure depends directly on these microscopic structures. For younger patients displaying signs of cannabis use disorder, digital mHealth tracking combined with targeted telehealth provides immediate real-world support. Tracking neurocognitive parameters during planned abstinence periods gives clinicians baseline measurements of memory recovery, showing how executive functions recalibrate after heavy use ceases.

DigestCannabis NewsRegulationPublic HealthClinical Practice

AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers.
Primary TopicClinical and policy analysis: Clinical Trial: Cannabis Abstinence and Neurocognitive .
Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42969874/)

Table of Contents

- [Clinical Trial: Cannabis Abstinence and Neurocognitive Assessment in Adolescence](#Clinical_Trial_Cannabis_Abstinence_and_Neurocognitive_Assessment_in_Adolescence)[How to Interpret This Cannabis News & Regulatory Digest](#How_to_Interpret_This_Cannabis_News_Regulatory_Digest)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading)
- [CED Perspective Lens: Eight Viewpoints on These Updates](#CED_Perspective_Lens_Eight_Viewpoints_on_These_Updates)[Understanding Your Products and Cognitive Recovery](#Understanding_Your_Products_and_Cognitive_Recovery)
- [Translating Plant Biology into Behavioral Patient Care](#Translating_Plant_Biology_into_Behavioral_Patient_Care)
- [Managing High Potency and Cognitive Safeguards](#Managing_High_Potency_and_Cognitive_Safeguards)
- [Standardizing Testing and Youth Digital Healthcare Access](#Standardizing_Testing_and_Youth_Digital_Healthcare_Access)
- [Linking Botanical Structure with Clinical Trial Frameworks](#Linking_Botanical_Structure_with_Clinical_Trial_Frameworks)
- [Evaluating Protocol Limitations and Self-Report Biases](#Evaluating_Protocol_Limitations_and_Self-Report_Biases)
- [Supporting Young Adults Through Digital Tools](#Supporting_Young_Adults_Through_Digital_Tools)
- [Integrating Plant Science with Modern Behavioral Care](#Integrating_Plant_Science_with_Modern_Behavioral_Care)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

# Clinical Trial: Cannabis Abstinence and Neurocognitive Assessment in Adolescence

A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research.

What This Study Teaches Us
Botanical research maps how capitate-stalked, capitate-sessile, and bulbous glandular trichomes concentrate cannabinoids and terpenes across floral bracts and vegetative leaves. Clinical protocols evaluate mobile mHealth platforms paired with remote counseling to reduce daily consumption in young adults with cannabis use disorder. Parallel trial designs track adolescent neurocognitive recovery across memory and executive function domains during structured cannabis abstinence.

Why This Matters
Understanding trichome distribution helps clinicians evaluate product potency and terpene profiles to guide safer dosing strategies. Digital interventions paired with abstinence tracking offer actionable tools to protect developing adolescent brains from long-term cognitive disruptions.

Study SnapshotPost TypeCannabis News & Regulatory Digest using canonical CED layoutItems Reviewed3 verified updatesPrimary DatesNovember 02, 2026Related Reading3 verified live CED Clinic internal linksUpdate 1Correction: Telehealth-Plus-mHealth Intervention for Young (Shrier et al., JMIR research protocols) [DOI: 10.2196/110610 | PMID: 42969874]Update 2A complex story of trichome (Shtein et al., Journal of Cannabis Research) [DOI: 10.1186/s42238-026-00529-2]Update 3Cannabis Abstinence and Neurocognitive Assessment (University Hospital Pilsen Regulatory Analysis)

Clinical Bottom Line
This clinical and regulatory overview preserves key signals across 3 updates without overstatement, offering grounded guidance for patients and practitioners.

Context Across These 3 Updates

This curated cannabis news & regulatory digest brings together 3 key developments across policy movements, regulatory milestones, and public health communications. Reviewing these distinct updates side by side clarifies emerging patterns while preserving the specific clinical context of each report.

Examining these developments concurrently helps clinicians, patients, and families trace the broader trajectory of the field while grounding practical decisions in verified primary data.

Update 1: Correction: Telehealth-Plus-mHealth Intervention for Young Adults With Cannabis

**Title & Source:** [Correction: Telehealth-Plus-mHealth Intervention for Young Adults With Cannabis Use Disorder: Protocol for a Pilot Randomized Controlled Trial.](https://pubmed.ncbi.nlm.nih.gov/42969874/) (*JMIR research protocols*, 2026Nov02)

**Lead Authors & Identifiers:** Lydia A Shrier, Madison M O’Connell, Avery Palmer, Sarah Parker et al.. | **Primary Record:** DOI: 10.2196/110610 | PMID: 42969874 Content lane: **Clinical Evidence Update**.

**Investigational Focus:** This trial protocol describes a combined telehealth and mobile health intervention designed for young adults facing cannabis use disorder. The study structure evaluates real-time app tracking alongside remote counseling check-ins.

**Key Findings & Primary Data:** The pilot randomized controlled trial design establishes protocols for tracking daily cravings, usage events, and counseling engagement. The framework standardizes delivery metrics across remote digital platforms for young adult cohorts.

**Clinical Guidance:** Mobile applications provide accessible support between scheduled office visits for young adult patients. Combining automated behavioral prompts with video counseling creates clear accountability.

**Study Boundaries:** The publication details trial methodologies and protocol corrections without presenting final patient treatment outcomes.

Update 2: A complex story of trichome types and chemistry

**Title & Source:** [A complex story of trichome types and chemistry in Cannabis vegetative and reproductive organs](https://doi.org/10.1186/s42238-026-00529-2) (*Journal of Cannabis Research*, 2026-10-31)

**Lead Authors & Identifiers:** Ilana Shtein, Nirit Bernstein. | **Primary Record:** DOI: 10.1186/s42238-026-00529-2 Content lane: **Clinical Evidence Update**.

**Investigational Focus:** This scientific review examines glandular and non-glandular trichome distribution across vegetative and reproductive organs in cannabis plants. The authors analyze how structural variation impacts terpene and cannabinoid synthesis.

**Key Findings & Primary Data:** Capitate-stalked trichomes on female floral bracts contain higher concentrations of THC, CBD, and monoterpenes compared to capitate-sessile or bulbous types. Vegetative leaves present predominantly non-glandular and sessile structures with lower secondary metabolite yields.

**Clinical Guidance:** Flower-derived products carry substantially higher resin concentrations than leaf-derived preparations due to trichome geography. Clinicians should account for plant organ origin when anticipating product strength and patient response.

**Study Boundaries:** Structural observations vary across distinct genetic cultivars, environmental conditions, and harvesting timelines.

Update 3: Cannabis Abstinence and Neurocognitive Assessment in Adolescence

**Title & Source:** [Clinical Trial: Cannabis Abstinence and Neurocognitive Assessment in Adolescence](https://clinicaltrials.gov/study/NCT07160153) (*University Hospital Pilsen*, 2026-11-02)

**Lead Authors & Identifiers:** University Hospital Pilsen. Content lane: **Protocol Watch**.

**Regulatory Context:** This active clinical trial at University Hospital Pilsen investigates neurocognitive performance in adolescents undergoing formal cannabis abstinence. The protocol tracks memory, attention, and executive function improvements over structured non-use intervals.

**Operative Findings:** The study protocol recruits adolescent participants to measure baseline cognitive deficits and track recovery patterns during verified abstinence. Standardized neurocognitive batteries evaluate processing speed, executive function, and working memory.

**Clinical Relevance:** Structured abstinence periods help clinicians separate temporary cognitive slowing from baseline neurological function. Demonstrating measurable cognitive recovery encourages sustained behavioral change in young patients.

**Practical Boundaries:** The study remains in active recruitment, so definitive recovery timelines and effect sizes are not yet available.

How Strong Is This Evidence?
The evidence base spans microscopic botanical characterization, an active clinical trial protocol evaluating digital interventions, and a recruiting trial examining cognitive recovery. These studies offer clear methodological blueprints, though two representing trial protocols currently lack published outcome data.

Where This Paper Deserves Skepticism
Botanical trichome density varies widely across specific cultivars and growing environments, limiting broad generalizations about plant chemistry. The clinical trials rely on self-reported abstinence and participant adherence to digital applications, which introduces potential reporting bias.

What This Paper Does Not Show
These papers do not prove that digital therapy permanently resolves cannabis use disorder in all young adults. They also do not establish exact timelines for full neurocognitive recovery following adolescent cannabis cessation.

How This Fits With the Broader Clinical Conversation

Modern cannabis research links plant structural biology directly with clinical outcomes. High concentrations of cannabinoids and monoterpenes accumulate within the secretory cavities of capitate-stalked trichomes, which line the female inflorescence. Variations in light, temperature, and organ maturity alter these resin glands, creating distinct chemical profiles that affect patient responses and therapeutic windows.

Simultaneously, digital health interventions address the rising demand for accessible adolescent and young adult care. Remote monitoring applications paired with brief motivational telehealth sessions allow clinicians to track real-time cravings and usage patterns. Integrating objective neurocognitive testing during formal abstinence periods provides a measurable pathway to evaluate brain recovery and cognitive resilience in developing individuals.

Editorial Commentary

*Patient care improves when we bridge botanical science and practical behavioral tools. Understanding trichome maturity and glandular distribution explains why two plant samples from the same crop produce noticeably different clinical effects. Higher densities of mature capitate trichomes deliver concentrated cannabinoid loads, requiring careful dose titrations for sensitive individuals.*

*When managing young adults with frequent use patterns, mobile tracking applications offer immediate visibility into daily triggers. Combining digital logs with remote clinical check-ins helps patients stabilize their consumption without feeling isolated. Observing cognitive improvements during brief abstinence windows gives patients tangible evidence of their brain recovery, reinforcing healthier long-term patterns.*

What a Careful Reader Should Take Away
Clinicians should match patient dosing strategies to botanical resin profiles while using digital support tools to monitor consumption and cognitive recovery in younger populations.

[https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this study:[🛡️Use Disorder](https://cedclinic.com/ask)[🧸Children and Teens](https://cedclinic.com/ask)[🏛️Law and Policy](https://cedclinic.com/ask)[🔎This study's limits](https://cedclinic.com/ask)

Evidence Interpretation Guide

## How to Interpret This Cannabis News & Regulatory Digest

Synthesizing botanical plant structure with active clinical trial protocols helps clinicians connect plant chemistry to patient recovery trajectories.

### Three Rules for Critical Reading

**Distinguish Botanical Structure from Clinical Dose**Recognize that trichome type and density directly govern cannabinoid concentration on plant surfaces.

**Separate Protocol Design from Published Data**Differentiate between early-stage clinical trial registrations and fully published trial outcome datasets.

**Track Cognitive Markers Over Time**Evaluate adolescent neurocognitive changes across formal periods of documented abstinence rather than brief single measurements.

Key Evaluation Question
How do specific trichome density patterns influence product potency, and how effectively do digital applications support sustained cognitive recovery?

The Patient Question
How might taking a structured break from cannabis affect my memory, attention, and daily focus?

The Bottom Line
Connecting plant structural chemistry with structured digital interventions creates a clear path for safe dosing and cognitive recovery.

CED Perspective Lens

## CED Perspective Lens: Eight Viewpoints on These Updates

Why these developments matter across clinical, patient, safety, and policy perspectives

Lens OverviewEight distinct clinical and regulatory perspectives on Clinical Trial: Cannabis Abstinence and Neuro.

#### Understanding Your Products and Cognitive Recovery

Understanding how cannabis plant glands produce active compounds helps you choose products with predictable chemical strength. Knowing how your brain recovers during structured breaks from cannabis gives you actionable targets for improving memory, attention, and mental clarity.

Digital support apps provide daily reminders and real-time progress tracking to help you reduce consumption or complete a planned break. Using these tools lets you measure clear improvements in your overall focus and executive function over time. In clinical practice, evaluating patient factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.

Lens takeawayTracking your progress digitally while taking structured breaks supports cognitive recovery and healthy routines.

#### Translating Plant Biology into Behavioral Patient Care

Botanical trichome structure directly dictates cannabinoid density, explaining chemical variations across floral bracts and vegetative plant tissues. Clinicians must account for these structural variations when evaluating self-reported patient dosages, identifying product potencies, and selecting whole-plant therapeutic formulations.

Pairing digital mHealth applications with brief remote consultations offers structured support for younger individuals with cannabis use disorder. Objective neurocognitive assessments during abstinence periods provide concrete benchmarks for cognitive recovery and therapeutic planning. In clinical practice, evaluating clinician factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.

Lens takeawayCombining plant chemistry awareness with digital interventions optimizes therapeutic outcomes and monitors cognitive recovery.

#### Managing High Potency and Cognitive Safeguards

Safety protocols depend on clear understanding of trichome density, as capitate-stalked glands yield high THC concentrations that elevate intoxication risk. Standardizing clinical dosage recommendations requires understanding plant organ anatomy and secondary metabolite accumulation mechanisms.

Monitoring young adults through digital health applications helps identify rising consumption patterns before severe dependence develops. Tracking cognitive performance during deliberate abstinence periods verifies safety margins and rules out lingering mental impairment. In clinical practice, evaluating safety factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.

Lens takeawayAccurate chemical profile assessment and digital monitoring prevent accidental overconsumption and support patient safety.

#### Standardizing Testing and Youth Digital Healthcare Access

Regulatory frameworks benefit from clear standards regarding botanical trichome testing and organ-specific chemical labeling. Distinguishing between high-density floral resin glands and low-potency vegetative leaves supports consistent product safety and quality control across commercial markets.

Supporting clinical trial infrastructure for digital health interventions offers scalable solutions for public health systems. Implementing evidence-based mHealth programs creates accessible care options for younger demographics experiencing heavy cannabis use disorder. In clinical practice, evaluating policy factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.

Lens takeawayEvidence-grounded regulation requires accurate product potency standards and expanded public funding for digital health programs.

#### Linking Botanical Structure with Clinical Trial Frameworks

Investigating trichome morphotypes and metabolite biosynthesis pathways deepens our scientific knowledge of plant development and cannabinoid yield. Mapping how environmental factors alter glandular development provides essential baseline data for standardized botanical medicine cultivation.

Rigorous trial methodologies combining mHealth tools with validated neurocognitive testing establish reliable clinical outcome metrics. Longitudinal data tracking cognitive recovery during controlled abstinence will clarify underlying brain plasticity mechanisms in adolescent populations. In clinical practice, evaluating research factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.

Lens takeawayCombining microscopic botanical analysis with rigorous digital trial designs advances clinical research in cannabis medicine.

#### Evaluating Protocol Limitations and Self-Report Biases

Methodological caution is necessary when evaluating self-reported data in digital health intervention trials for young adults. Without strict biochemical verification, self-reported reductions in consumption can reflect reporting bias rather than genuine behavioral change.

Botanical studies on trichome density cannot fully predict patient outcomes, as individual metabolic variations alter cannabinoid absorption. Clinical trial protocols must publish complete, peer-reviewed outcome datasets before digital apps are widely adopted in standard care. In clinical practice, evaluating skeptic factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.

Lens takeawayObjective biochemical validation and published outcome data are essential to confirm the effectiveness of digital interventions.

#### Supporting Young Adults Through Digital Tools

Caregivers supporting young adults with heavy cannabis use disorder gain valuable structure from digital mHealth tracking applications. Remote counseling options make professional clinical guidance more accessible while maintaining transparent communication between patients and care teams.

Understanding that cognitive clarity returns during structured abstinence provides strong encouragement for families helping young individuals navigate recovery. Observing gradual improvements in memory and daily focus validates the effort required to reduce heavy cannabis consumption. In clinical practice, evaluating caregiver factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.

Lens takeawayDigital intervention tools and cognitive recovery milestones offer practical guidance and hope for family members supporting recovery.

#### Integrating Plant Science with Modern Behavioral Care

Integrating botanical chemistry research with modern digital care platforms yields a balanced, evidence-based approach to cannabis medicine. Recognizing how trichome structures drive potency helps clinicians refine dosage protocols for diverse patient populations.

Simultaneously, digital mHealth applications paired with neurocognitive testing provide practical mechanisms for monitoring adolescent brain recovery during periods of abstinence. These combined strategies ensure clinical care remains grounded in objective science and practical harm reduction. In clinical practice, evaluating takeaway factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.

Lens takeawayCombining structural plant science with digital behavioral monitoring supports safer clinical practice and objective patient recovery tracking.

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

 
 Physician-Led, Whole-Person Care
 [Dr. Benjamin Caplan, MD](https://cedclinic.com/drcaplan/)
 Board-Certified Family Physician • Cannabinoid Specialist • 350k+ Patients Evaluated
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.

 
 Health, Longevity, Wellness
 One-on-One Cannabis Guidance
 Metabolic Balance
 

 
 [Meet Dr. Caplan (CV)](https://cedclinic.com/drcaplan/)
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](http://CEDclinic.com/book)
 [Cannabis Care](http://CEDclinic.com/book)
 
 

 
 [https://cedclinic.com/drcaplan/](https://cedclinic.com/drcaplan/)
 
 

Share this Evidence Watch

[X](https://twitter.com/intent/tweet?text=Clinical+Trial%3A+Cannabis+Abstinence+and+Neurocognitive+Assessment+in+Adolescence&url=https%3A%2F%2Fcedclinic.com%2Fced-botanical-chemistry-mobile-cud-interventions-2026-11-02%2F)
[LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-botanical-chemistry-mobile-cud-interventions-2026-11-02%2F)
[BlueSky](https://bsky.app/intent/compose?text=Clinical+Trial%3A+Cannabis+Abstinence+and+Neurocognitive+Assessment+in+Adolescence%20https%3A%2F%2Fcedclinic.com%2Fced-botanical-chemistry-mobile-cud-interventions-2026-11-02%2F)
[Instagram](https://www.instagram.com/drcaplan/)
[Substack](https://doctorapprovedcannabis.substack.com/)
[RSS](https://cedclinic.com/feed/)

Source: [Primary Sources: JMIR research protocols, Journal of Cannabis Research, University Hospital Pilsen](https://pubmed.ncbi.nlm.nih.gov/42969874/)

Related Reading at CED ClinicContinue exploring the evidence[Cannabis Use Disorder Is Rising Among US Adults](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/)

More on this topic: Epidemiological evaluation of diagnostic trends, screening tools, and evidence-based patient counseling.

[More on this topic: CUD trends & screening](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/)[Prenatal Cannabis Exposure and Neurodevelopment: What the New Systematic Review Actually Shows](https://cedclinic.com/prenatal-cannabis-neurodevelopment-impact/)

More on this topic: Systematic review analyzing cognitive, behavioral, and developmental trajectories following gestational cannabinoid exposure.

[More on this topic: Fetal neurodevelopment](https://cedclinic.com/prenatal-cannabis-neurodevelopment-impact/)[Adolescent Cannabis Use and Its Impact on Cognitive Development: Insights from the ABCD Study](https://cedclinic.com/adolescent-cannabis-use-cognitive-development-risk/)

More on this topic: Long-term ABCD study findings on adolescent brain development, executive function, and early cannabis susceptibility.

[More on this topic: Adolescent brain health](https://cedclinic.com/adolescent-cannabis-use-cognitive-development-risk/)

## Frequently Asked Questions

What is covered in this cannabis news & regulatory digest?

This edition reviews 3 verified developments across cannabis policy, regulatory oversight, and clinical science.

How are stories selected for CED digests?

Stories are curated from official primary sources, government agency dockets, and peer-reviewed journals, focusing on practical relevance for patients and clinicians.

Do preliminary reports establish medical efficacy?

No. Observational reports, preprints, and regulatory filings describe emerging trends and require formal clinical trials before treatment efficacy can be claimed.

How should clinicians use these updates?

Clinicians can use these updates to understand patient questions, stay current with state regulations, and maintain evidence-informed counseling.

Where can readers find Dr. Caplan's clinical insights?

Dr. Caplan provides comprehensive clinical perspectives, patient consultations, and educational resources at CEDclinic.com.

Why are multi-topic digests published instead of single stories?

Digests group related updates together to provide a broader thematic overview while preserving important nuances and methodological limits.

What is the primary role of laboratory testing in cannabis policy?

Laboratory testing verifies cannabinoid potency and screens for harmful contaminants like heavy metals, pesticides, and molds to protect consumer health.

How do state regulatory milestones impact patient access?

Administrative milestones establish the licensing rules, product categories, and retail standards that determine how and where registered patients obtain care.

What precautions should families take with medical cannabis at home?

Families should keep all medical cannabis products securely locked in child-resistant containers and clearly labeled to avoid accidental exposure.

How often does CED Clinic publish clinical and policy updates?

CED Clinic publishes regular morning, afternoon, and evening evidence reviews and news digests to keep the community informed.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).